Dr Thomas Kleen, a specialist in designing immune monitoring technologies, has joined Immodulon Therapeutics Ltd in Uxbridge, England, as chief scientific officer. He most recently served as an executive vice president for immune monitoring at Precision for Medicine Group LLC, a consultancy based in Washington, DC, US. Immodulon Therapeutics is developing treatments for advanced melanoma and for advanced pancreatic cancer.
Immodulon Therapeutics announced the appointment on 23 May 2019.
Copyright 2019 Evernow Publishing Ltd